Eprenetapopt (APR-246) is a first-in-class small-molecule p53 reactivator that induces apoptosis also in TP53-mutated leukemic cells and could be the first FDA-approved targeted therapy for TP53-mutated AML. This evidence concerns the gene TP53 and acute myeloid leukemia.